Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus Vinorelbine in HER2+ Metastatic Breast Cancer
NCT01730677Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2012
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in HER2-positive metastatic breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01730677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730677.